813 related articles for article (PubMed ID: 28724364)
1. Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells.
Wang Q; Cheng Y; Wang Y; Fan Y; Li C; Zhang Y; Wang Y; Dong Q; Ma Y; Teng YE; Qu X; Liu Y
BMC Cancer; 2017 Jul; 17(1):492. PubMed ID: 28724364
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
[TBL] [Abstract][Full Text] [Related]
3. Induction of the mesenchymal to epithelial transition by demethylation- activated microRNA-200c is involved in the anti-migration/invasion effects of arsenic trioxide on human breast cancer cells.
Si L; Jiang F; Li Y; Ye X; Mu J; Wang X; Ning S; Hu C; Li Z
Mol Carcinog; 2015 Sep; 54(9):859-69. PubMed ID: 24729530
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-200c Inhibits the Metastasis of Triple-Negative Breast Cancer by Targeting ZEB2, an Epithelial-Mesenchymal Transition Regulator.
Chen H; Li Z; Zhang L; Zhang L; Zhang Y; Wang Y; Xu M; Zhong Q
Ann Clin Lab Sci; 2020 Jul; 50(4):519-527. PubMed ID: 32826250
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase 7B/microRNA-200c relationship regulates triple-negative breast cancer cell growth.
Zhang DD; Li Y; Xu Y; Kim J; Huang S
Oncogene; 2019 Feb; 38(7):1106-1120. PubMed ID: 30209363
[TBL] [Abstract][Full Text] [Related]
6. miR-200c/PAI-2 promotes the progression of triple negative breast cancer via M1/M2 polarization induction of macrophage.
Meng Z; Zhang R; Wang Y; Zhu G; Jin T; Li C; Zhang S
Int Immunopharmacol; 2020 Apr; 81():106028. PubMed ID: 31801690
[TBL] [Abstract][Full Text] [Related]
7. Isoliquiritigenin Suppresses EMT-Induced Metastasis in Triple-Negative Breast Cancer through miR-200c/C-JUN/[Formula: see text]-Catenin.
Peng F; Tang H; Du J; Chen J; Peng C
Am J Chin Med; 2021; 49(2):505-523. PubMed ID: 33641651
[TBL] [Abstract][Full Text] [Related]
8. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J
Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463
[TBL] [Abstract][Full Text] [Related]
9. Reversal of Triple-Negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of Immunosuppression.
Rogers TJ; Christenson JL; Greene LI; O'Neill KI; Williams MM; Gordon MA; Nemkov T; D'Alessandro A; Degala GD; Shin J; Tan AC; Cittelly DM; Lambert JR; Richer JK
Mol Cancer Res; 2019 Jan; 17(1):30-41. PubMed ID: 30213797
[TBL] [Abstract][Full Text] [Related]
10. Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition.
Su CM; Lee WH; Wu AT; Lin YK; Wang LS; Wu CH; Yeh CT
J Nutr Biochem; 2015 Jun; 26(6):675-85. PubMed ID: 25792283
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
Choi SK; Kim HS; Jin T; Hwang EH; Jung M; Moon WK
BMC Cancer; 2016 Aug; 16():570. PubMed ID: 27484639
[TBL] [Abstract][Full Text] [Related]
12. Antrodia camphorata inhibits epithelial-to-mesenchymal transition by targeting multiple pathways in triple-negative breast cancers.
Hseu YC; Chang GR; Pan JY; Rajendran P; Mathew DC; Li ML; Liao JW; Chen WT; Yang HL
J Cell Physiol; 2019 Apr; 234(4):4125-4139. PubMed ID: 30146779
[TBL] [Abstract][Full Text] [Related]
13. Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of β-catenin expression.
Lin D; Kuang G; Wan J; Zhang X; Li H; Gong X; Li H
Oncol Rep; 2017 Feb; 37(2):895-902. PubMed ID: 27959422
[TBL] [Abstract][Full Text] [Related]
14. Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells.
Manavalan TT; Teng Y; Litchfield LM; Muluhngwi P; Al-Rayyan N; Klinge CM
PLoS One; 2013; 8(4):e62334. PubMed ID: 23626803
[TBL] [Abstract][Full Text] [Related]
15. MiR-212-5p Suppresses the Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer by Targeting Prrx2.
Lv ZD; Yang DX; Liu XP; Jin LY; Wang XG; Yang ZC; Liu D; Zhao JJ; Kong B; Li FN; Wang HB
Cell Physiol Biochem; 2017; 44(5):1785-1795. PubMed ID: 29216628
[TBL] [Abstract][Full Text] [Related]
16. microRNA-200c/141 upregulates SerpinB2 to promote breast cancer cell metastasis and reduce patient survival.
Jin T; Suk Kim H; Ki Choi S; Hye Hwang E; Woo J; Suk Ryu H; Kim K; Moon A; Kyung Moon W
Oncotarget; 2017 May; 8(20):32769-32782. PubMed ID: 28427146
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer.
Di L; Liu LJ; Yan YM; Fu R; Li Y; Xu Y; Cheng YX; Wu ZQ
J Exp Clin Cancer Res; 2019 Mar; 38(1):134. PubMed ID: 30898152
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen represses miR-200 microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating c-Myc in endometrial carcinoma cell lines.
Bai JX; Yan B; Zhao ZN; Xiao X; Qin WW; Zhang R; Jia LT; Meng YL; Jin BQ; Fan DM; Wang T; Yang AG
Endocrinology; 2013 Feb; 154(2):635-45. PubMed ID: 23295740
[TBL] [Abstract][Full Text] [Related]
19. MiR-508-3p inhibits cell invasion and epithelial-mesenchymal transition by targeting ZEB1 in triple-negative breast cancer.
Guo SJ; Zeng HX; Huang P; Wang S; Xie CH; Li SJ
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6379-6385. PubMed ID: 30338806
[TBL] [Abstract][Full Text] [Related]
20. Isochlorogenic Acid C Reverses Epithelial-Mesenchymal Transition
Yu JK; Yue CH; Pan YR; Chiu YW; Liu JY; Lin KI; Lee CJ
Anticancer Res; 2018 Apr; 38(4):2127-2135. PubMed ID: 29599331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
